BlackRock’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$861M Sell
3,798,560
-60,540
-2% -$10.8M 0.01% 852
2026
Q1
$666M Buy
3,859,100
+104,746
+3% +$19.4M 0.01% 912
2025
Q4
$749M Sell
3,754,354
-101,712
-3% -$18.4M 0.01% 838
2025
Q3
$603M Buy
3,856,066
+199,934
+5% +$31.8M 0.01% 964
2025
Q2
$555M Sell
3,656,132
-14,693
-0.4% -$1.96M 0.01% 990
2025
Q1
$553M Sell
3,670,825
-561,345
-13% -$94.1M 0.01% 969
2024
Q4
$781M Sell
4,232,170
-6,166
-0.1% -$1.19M 0.02% 780
2024
Q3
$835M Sell
4,238,336
-849,681
-17% -$177M 0.02% 733
2024
Q2
$1.05B Sell
5,088,017
-83,767
-2% -$19M 0.02% 567
2024
Q1
$1.4B Buy
5,171,784
+10,424
+0.2% +$2.49M 0.03% 473
2023
Q4
$1.22B Buy
5,161,360
+40,793
+0.8% +$8.02M 0.03% 504
2023
Q3
$1B Sell
5,120,567
-77,470
-1% -$15.9M 0.03% 528
2023
Q2
$1.09B Buy
5,198,037
+411,153
+9% +$81.8M 0.03% 510
2023
Q1
$966M Sell
4,786,884
-171,343
-3% -$38.8M 0.03% 548
2022
Q4
$1.08B Sell
4,958,227
-350,971
-7% -$76.6M 0.03% 487
2022
Q3
$1.04B Sell
5,309,198
-17,014
-0.3% -$3.67M 0.04% 472
2022
Q2
$1.14B Buy
5,326,212
+96,179
+2% +$23.5M 0.04% 467
2022
Q1
$1.49B Buy
5,230,033
+150,007
+3% +$46.3M 0.04% 443
2021
Q4
$1.91B Sell
5,080,026
-7,667
-0.2% -$2.98M 0.05% 375
2021
Q3
$2.1B Buy
5,087,693
+152,682
+3% +$63.4M 0.06% 321
2021
Q2
$1.83B Sell
4,935,011
-656,200
-12% -$219M 0.05% 363
2021
Q1
$1.62B Buy
5,591,211
+221,598
+4% +$61.6M 0.05% 389
2020
Q4
$1.34B Buy
5,369,613
+20,073
+0.4% +$4.78M 0.04% 424
2020
Q3
$1.21B Buy
5,349,540
+8,157
+0.2% +$1.69M 0.04% 393
2020
Q2
$931M Buy
5,341,383
+877,241
+20% +$140M 0.04% 455
2020
Q1
$563M Sell
4,464,142
-29,811
-0.7% -$4.47M 0.03% 557
2019
Q4
$686M Sell
4,493,953
-114,797
-2% -$15.9M 0.03% 627
2019
Q3
$610M Sell
4,608,750
-51,878
-1% -$6.96M 0.03% 630
2019
Q2
$661M Buy
4,660,628
+72,827
+2% +$9.88M 0.03% 603
2019
Q1
$666M Buy
4,587,801
+57,789
+1% +$7.59M 0.03% 587
2018
Q4
$513M Buy
4,530,012
+18,491
+0.4% +$2.32M 0.03% 642
2018
Q3
$607M Buy
4,511,521
+64,556
+1% +$7.97M 0.03% 647
2018
Q2
$499M Buy
4,446,965
+292,685
+7% +$31.6M 0.02% 733
2018
Q1
$443M Buy
4,154,280
+119,962
+3% +$12.9M 0.02% 783
2017
Q4
$442M Buy
4,034,318
+31,676
+0.8% +$3.45M 0.02% 785
2017
Q3
$432M Sell
4,002,642
-20,240
-0.5% -$2.08M 0.02% 755
2017
Q2
$407M Buy
4,022,882
+177,239
+5% +$16.3M 0.02% 762
2017
Q1
$346M Buy
3,845,643
+3,815,298
+12,573% +$324M 0.02% 867
2016
Q4
$2.31M Buy
30,345
+123
+0.4% +$9.34K ﹤0.01% 1174
2016
Q3
$2.52M Sell
30,222
-15,331
-34% -$1.29M ﹤0.01% 1118
2016
Q2
$3.76M Buy
45,553
+14,455
+46% +$1.19M 0.01% 946
2016
Q1
$2.36M Sell
31,098
-71,645
-70% -$5.3M ﹤0.01% 1061
2015
Q4
$8.26M Sell
102,743
-38,251
-27% -$2.76M 0.01% 726
2015
Q3
$8.96M Buy
140,994
+300
+0.2% +$21.5K 0.01% 654
2015
Q2
$9.9M Sell
140,694
-38,771
-22% -$2.87M 0.01% 669
2015
Q1
$14.2M Buy
179,465
+24,320
+16% +$1.79M 0.02% 606
2014
Q4
$9.87M Sell
155,145
-120,094
-44% -$7.53M 0.01% 677
2014
Q3
$16.4M Sell
275,239
-15,546
-5% -$889K 0.02% 567
2014
Q2
$15.6M Sell
290,785
-193,569
-40% -$10.6M 0.02% 574
2014
Q1
$29.2M Buy
484,354
+478,332
+7,943% +$27.9M 0.05% 408
2013
Q4
$319K Buy
6,022
+1
+0% +$50 ﹤0.01% 1479
2013
Q3
$278K Hold
6,021
﹤0.01% 1415
2013
Q2
$247K Buy
+6,021
New +$258K ﹤0.01% 1443

Other funds holding CRL

BlackRock's CRL Position: Q2 2026 in Review

BlackRock reduced its Charles River Laboratories (CRL) stake by 1.6% in Q2 2026, selling an estimated $10.8M and leaving 3,798,560 shares worth $861M. The position accounts for 0.01% of the portfolio, ranked #852.

BlackRock first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.1B in Q3 2021. 565 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • BlackRock held 3,798,560 shares of Charles River Laboratories worth $861M as of Q2 2026.
  • BlackRock sold 60,540 Charles River Laboratories shares in Q2 2026, an estimated $10.8M.
  • Charles River Laboratories made up 0.01% of BlackRock's portfolio in Q2 2026, its #852 holding.
  • BlackRock first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's Charles River Laboratories position peaked at $2.1B in Q3 2021.
  • 565 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.